SGX945 dusquetide Updated Nov 9
Watch for any announcement from Soligenix regarding the next development steps for SGX945, including potential Phase 3 trial plans or a partnership/licensing deal. The company is actively evaluating strategic alternatives, so any M&A or partnership news could be a major catalyst. Also monitor for any new clinical trial initiations or regulatory milestone updates.
- SGX945 (dusquetide) achieved 7 of 8 patients with complete response of oral ulcers in a Phase 2a proof-of-concept study, with no treatment-related adverse events, comparing favorably to Otezla's side effect profile (diarrhea 41%, nausea 19%, headache 14%).
- The drug has received multiple regulatory designations: FDA Fast Track (Jan 2024), FDA Orphan Drug (Aug 2025), EMA positive opinion and EU Orphan Drug (Feb-Mar 2026), and UK MHRA Promising Innovative Medicine designation (Mar 2026), indicating regulatory support.
- SGX945 uses a novel innate defense regulator (IDR) mechanism that modulates the immune system rather than suppressing it, potentially offering a differentiated safety profile versus existing treatments.
- Soligenix has a market cap of roughly $7.6M and only $9.0M in cash (as of September 30, 2026), limiting its ability to fund a large Phase 3 trial without significant dilution or a partnership.
- The Phase 3 FLASH2 trial for HyBryte (the company's other lead asset) was terminated in 2026 after disappointing interim results, raising questions about Soligenix's clinical development capabilities.
- The company has conducted multiple ATM equity offerings in 2026, causing substantial shareholder dilution. The stock trades around $0.335, near its 52-week low of $0.28.